Focused on bioactive raw materials, we are rooted in Industry-Academia collaboration with Xiamen University's NIDVD and a lead role in China's National 863 Program, giving us a strong foundation for innovation. Our platforms combine E. coli, CHO, HEK293, and insect cell expression systems with multi-species antibody screening, enabling full-matrix development and high-throughput screening. Our 300+ high-performance raw materials are compatible with POCT FIA, RDT, ELISA, CLIA, and PCR diagnostics, as well as third-party controls and serum panels. INNOBIOMAX raw materials, proven across WANTAI and INNODX production lines for decades, are validated by WHO PQ or recommendation for HIV and TB-IGRA kits. We partner with global IVD manufacturers to advance public health through world-class raw materials.